Member Info for JSB1989

Just Jimmy - It’s already up 50%. I’d call that a good response!

Following on from my point last night about financing, I fully expect a similar type of fundraising to Verona Pharma who were sitting at a £50 million market cap prior to this morning and have secured $200 million through US investors.

We are building US investor interest and with the US listing ‘on the cards’ as Duncan Peyton said, we are likely to be able to achieve such a transformational fundraise.

Hi Christo13, 4D has possibly overstretched itself with the number of clinical trials it currently has ongoing with 7 in total. That does however suggest to me that they are confident with the data coming out of the trials and they want to accelerate the platform forwards. After all these guys are putting their money forwards with £2.5 million from the board this year in the 2 placings.

The Covid-19 study has been added since the February placing and that was an opportunity they couldn't pass up. They have raised earlier than planned but I'd rather they do that now with the knowledge that they are funded through these significant readouts/inflection points than struggling to finish them.

I think that we will go down the routine of a US listing and with that will secure a significant amount of finance when this happens from US backers. We will need more cash likely by or before Q2 next year but drug development isn't cheap and with each raise they are adding value into the platform. Check out the latest presentation and you will see that we are planning a phase I/II trial in Neurodegenerative Disease with our drug MRx0029. The interest generated with big pharma will likely be significant with MRx0029 due to the unmet need in this area for effective drugs.

I'm not saying there aren't risks involved here, but a £45 million valuation on what 4D have developed is vastly undervalued. Success on one of the 7 or 8 trials will multiply the share price and repeated success for the platform is a billion dollar/pound valuation in my opinion.

Christo13 - I think you will find their is plenty of news in the near term up to Christmas/Early Q1 and any one could significantly change our valuation. I’ve summarised below:

- IBS readout & partnership to take any further trials forward

- Covid preliminary data

- Further Oncology data on a larger group size

- Neurodegeneration candidate development with first trials likely to commence in 2021

- Preliminary results of clinical biomarker oncology study

- Covid full readout

- US Listing / Financing

- Potential update on the vaccine development with Merck

Why would they exit by Christmas? The cash burn is high but considering we have a significant pipeline of trials it is worth the cost IMO. I think the next financing will involve the Americans and for a significant amount. The US listing looks likely and is a smart move for the company to attain a fair valuation for the platforms we have.

The RNS says that they will look for a partner to take Blautix forwards if the trial is successful and they are in talks about this. It’s clear that they are focusing resources now on MRx-0518 (oncology), MRx-4DP0004 (Asthma and Covid) and are keen to develop their two neurodegeneration strains. Blautix and Thetanix are likely to be licensed out to a partner, either a fellow LBP developer or a larger pharma who is interested in the microbiome space, Takeda has crossed my mind. Takeda have shown interest in the microbiome, particularly in GI disorders and have already formed partnerships with Enterome and Debiopharm.

Takeyourbets - are you actually AC? Your promotional rhetoric sounds very similar. You also say 4-6p this year? That’s a £30-45 million valuation. Have you seen the production numbers from other oilies who are at those valuations? UOG mostly in Egypt currently £18 million and 3000 barrels with much better assets and proven management.

That RNS this morning will come to nothing.

That will generate nothing and the placings will continue. 5 placings so far in 2020 already! Every acquisition or attempted one has been another failure since 2017. This is a lifestyle company which wasn’t sustainable at $75-80 a barrel and it now expects to be at $40 a barrel. I reckon 3-4 more placings this year to keep those lights on.

What deal has Cattaneo done that has benefitted the shareholders? When has he delivered in over three years since listing on the London market?

RRE did 30% last week, just moves under the radar compared to TLW and PMO.

The price may be a dog but the company certainly isn’t!

It lacked behind last Monday morning and went nuts in the afternoon. Good for closing above 1400 today!

Yes not good for them. AA will steer well clear of HUR. We don’t need to gamble and add any risky or problematic assets into the portfolio.

Would be awesome. Oil opened up just shy of $43 for Brent

I haven’t followed Premier or North Sea activity until very recently but it looks like Premier have bitten off far more than they can chew. Were they also acquiring these fields when the POO was at $70-80 prices?

Personally wouldn’t touch HUR with the water cut issues.

I think it will move to £15 by the end of the week. I see RRE as comparable to Serica who are trading close to pre covid levels. I fully expect RRE to do the same and continue heading back towards £20 soon.

Agreed about HUR, very risky and I don’t think AA would go from stable production and debt free to problematic wells and take on HUR’s debt.

Possibly Serica? Been researching RRE for a couple of weeks, unfortunately that’s meant paying £12+ instead of £9 or £10

Hur = a penny stock on AIM, will attract more people. No stamp duty, tight spread and very liquid. Risky as fook!

RRE= much cheaper and tiny risk compared to Hur

Paul - you are nuts with your prediction. 170p puts us at £120 Market Cap. We have done that in sales since February, less than 4 months. The sales are not going to dry up anytime soon. As our society reopens there will be testing on an even grander scale. If you get a cold, you will need a test before going back to work. The revenues by the winter could be huge and sure there will be many tests out there with a fairly saturated market but we know that Primerdesign is the gold standard PCR test and Novacyt have delivered on every promise.

If we did ever see £2 you can bet every man and his dog will be throwing money in. I think at these prices we are a real takeover target and one that will be too cheap in my opinion.

Stay patient, this is going to retrace to £1, won’t be long in my opinion!